NCT06657859View on ClinicalTrials.gov

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2029

Study Completion Date

October 31, 2029

Conditions

Pmm2-CDGPhosphomannomutase 2 Deficiency

Interventions

DRUG

GLM101

GLM101 IV infusion

Trial Locations (1)

08950

Hospital Sant Joan de Déu, Barcelona

Sponsors

Lead Sponsor

Glycomine, Inc.

All Listed Sponsors

lead

Glycomine, Inc.

INDUSTRY

NCT06657859 - Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients | Biotech Hunter | Biotech Hunter